All articles by Chemistry World – Page 28
-
Business
Business roundup: October 2010
Sanofi bid too low says Genzyme Source: © SANOFI AVENTIS Christopher Viehbacher: ’offer provides immediate and certain value Sanofi-Aventis is not being bashful about its designs on Genzyme any longer. The French pharma giant has offered $69 (£45) per share in an all-cash bid that values the ...
-
News
Nanocoat for restoring historic paintings
Historic wall paintings could be restored, thanks to an innovative nanoparticle coating
-
Podcast
September 2010
Chemistry World Podcast -September 201000:12- Introduction01:15- Recycling CO2 to make plastic 03:15- Snapshots of mystery molecules 06:10- Allison Carey from Yale University, US, on how mosquitoes sniff out meals and the chemicals we might use to stop getting bitten ...
-
Opinion
Letters: September 2010
It was interesting to read Matt Brown's article on the liaison between Tamil Nadu Agricultural University and Cornell
-
Business
Business roundup: September 2010
Falling sales at Johnson & Johnson ’s (J&J) consumer healthcare division have hurt the pharma giant’s US sales, which fell 2.8 per cent compared to the same period last year. Globally, sales for the company’s consumer goods division fell 5.4 per cent to $3.6 billion (£2.3 billion) - ...
-
Podcast
August 2010
Chemistry World Podcast - August 201000:12- Introduction01:31- First graphene touch screen 03:10- Microspheres help restore eyesight 06:08- Miles Congreve from Heptares Therapeutics talks about targeting G-protein-coupled receptors to develop new therapeutics ...
-
Opinion
Letters: August 2010
I was interested to read Philip Ball’s piece on the automated future of chemical crystallography, based on work at St Andrew’s University, Scotland, UK, to develop an entirely automatic diffractometer capable of ’flexible thinking’ designed to mimic the thought process of a crystallographer (Chemistry World, June 2010, p34). While this ...
-
Business
Business roundup: August 2010
Bittersweet victory for GSK’s Avandia GlaxoSmithKline (GSK) has received a muted ’thumbs up’ from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration (FDA) will allow the UK-based pharma giant to continue selling the drug in ...
-
News
Microspheres help restore eyesight
Polymer microspheres could deliver stem cells to the eyes of patients to help restore sight destroyed by a common eye disease